Over 500 million men worldwide suffer from erectile dysfunction and premature ejaculation. Dicot Pharma is developing an entirely new potency drug aimed at creating a treatment with longer duration, fewer side effects, and effectiveness for a significantly broader group compared to existing market alternatives.
Dicot Pharma’s World in Numbers
Major insight into LIB-01’s mechanism of action
New study findings show that LIB-01 affects the nervous and vascular structures that play an essential role for penile erection. This represents a fundamental difference from today’s erectile dysfunction drugs, which act locally within the erectile tissue.
Dutch TV highlights Swedish innovation
RTL’s channels reach 98% of the Dutch population every week. In one of their segments on innovative Swedish companies, Elin Trampe is interviewed about Dicot Pharma’s vision and the clinical work partly conducted in the Netherlands.
